Literature DB >> 16316416

Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.

G Batoni1, S Esin, F Favilli, M Pardini, D Bottai, G Maisetta, W Florio, M Campa.   

Abstract

Mycobacterium bovis bacillus Calmette-Guérin (BCG) is capable of directly stimulating several effector functions of human natural killer (NK) cells in the absence of interleukin-12 and professional antigen presenting cells. To assess the contribution of two main human NK-cell subsets (CD56(dim) and CD56(bright)) to the overall in vitro NK-cell response to BCG, peripheral blood mononuclear cells depleted of nylon wool-adherent cells or purified NK cells were stimulated with live BCG. By combining intranuclear bromodeoxyuridine (BrdU) staining and analysis of CD56 marker intensity, statistically higher percentages of BrdU(+) cells were found among the CD56(bright) subset than the CD56(dim) subset after 6 days of stimulation with BCG. Similarly, evaluation of intracellular interferon-gamma (IFN-gamma) revealed that CD56(bright) cells were those mainly involved in IFN-gamma production in response to BCG. In contrast, the CD56(dim) subset contained higher levels of perforin and granzyme A, two key molecules for exocytosis-mediated cytotoxicity, than the CD56(bright) subset. Although 16-20-h stimulation with BCG did not substantially alter the expression of cytotoxic molecules by the two subsets, a decrease in perforin content was observed in the CD56(dim), but not in the CD56(bright) subset, following 4-h incubation with the NK-sensitive target K562 cell line. This decrease in perforin content correlated with the induction by BCG-stimulated NK cells, of early markers of apoptosis on target cells to a greater extent than unstimulated cells suggesting a major role for the CD56(dim) subset in cytotoxic activity in response to BCG. Taken together, these results demonstrate that CD56(bright) and CD56(dim) human NK-cell subsets exert different functional activities in response to a live bacterial pathogen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316416     DOI: 10.1111/j.1365-3083.2005.01692.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  24 in total

1.  Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Authors:  Elisabetta Vulpis; Francesca Cecere; Rosa Molfetta; Alessandra Soriani; Cinzia Fionda; Giovanna Peruzzi; Giulio Caracciolo; Sara Palchetti; Laura Masuelli; Lucilla Simonelli; Ugo D'Oro; Maria Pia Abruzzese; Maria Teresa Petrucci; Maria Rosaria Ricciardi; Rossella Paolini; Marco Cippitelli; Angela Santoni; Alessandra Zingoni
Journal:  Oncoimmunology       Date:  2017-01-13       Impact factor: 8.110

2.  Characterization of a human anti-tumoral NK cell population expanded after BCG treatment of leukocytes.

Authors:  Eva M García-Cuesta; Gloria Esteso; Omodele Ashiru; Sheila López-Cobo; Mario Álvarez-Maestro; Ana Linares; Mei M Ho; Luis Martínez-Piñeiro; Hugh T Reyburn; Mar Valés-Gómez
Journal:  Oncoimmunology       Date:  2017-02-21       Impact factor: 8.110

Review 3.  Natural killer (NK) cells in antibacterial innate immunity: angels or devils?

Authors:  Fernando Souza-Fonseca-Guimaraes; Minou Adib-Conquy; Jean-Marc Cavaillon
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

4.  Impaired interferon-gamma production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia.

Authors:  J Reichenbach; R Schubert; J Feinberg; O Beck; M Rosewich; M A Rose; S Zielen
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

5.  Clinicopathological Manifestations and Immune Phenotypes in Adult-Onset Immunodeficiency with Anti-interferon-γ Autoantibodies.

Authors:  Yi-Chun Chen; Shao-Wen Weng; Jing-Ya Ding; Chen-Hsiang Lee; Cheng-Lung Ku; Wen-Chi Huang; Huey-Ling You; Wan-Ting Huang
Journal:  J Clin Immunol       Date:  2022-01-28       Impact factor: 8.317

6.  Escape of HIV-1-infected dendritic cells from TRAIL-mediated NK cell cytotoxicity during NK-DC cross-talk--a pivotal role of HMGB1.

Authors:  Marie-Thérèse Melki; Héla Saïdi; Alexandre Dufour; Jean-Christophe Olivo-Marin; Marie-Lise Gougeon
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

7.  Direct binding of human NK cell natural cytotoxicity receptor NKp44 to the surfaces of mycobacteria and other bacteria.

Authors:  Semih Esin; Giovanna Batoni; Claudio Counoupas; Annarita Stringaro; Franca Lisa Brancatisano; Marisa Colone; Giuseppantonio Maisetta; Walter Florio; Giuseppe Arancia; Mario Campa
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

8.  Evaluation of a simplified dual-platform flow cytometric method for measurement of lymphocyte subsets and T-cell maturation phenotypes in the population of Nouna, Burkina Faso.

Authors:  T Böhler; M von Au; N Klose; K Müller; B Coulibaly; F Nauwelaers; H P Spengler; G Kynast-Wolf; H-G Kräusslich
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

9.  Natural killer cells are recruited during pulmonary tuberculosis and their ex vivo responses to mycobacteria vary between healthy human donors in association with KIR haplotype.

Authors:  Damien Portevin; Laura E Via; Seokyong Eum; Douglas Young
Journal:  Cell Microbiol       Date:  2012-07-30       Impact factor: 3.715

10.  Phenotype of Peripheral NK Cells in Latent, Active, and Meningeal Tuberculosis.

Authors:  José Alberto Choreño-Parra; Luis Armando Jiménez-Álvarez; Ellis Daniela Maldonado-Díaz; Graciela Cárdenas; Luis Alejandro Fernández-Lopez; José Luis Soto-Hernandez; Marcela Muñoz-Torrico; Gustavo Ramírez-Martínez; Alfredo Cruz-Lagunas; Armando Vega-López; María Lilia Domínguez-López; Carlos Sánchez-Garibay; Parménides Guadarrama-Ortíz; Silvia Giono; Luis Antonio Jiménez-Zamudio; Shabaana A Khader; Ethel A García-Latorre; Citlaltepetl Salinas-Lara; Joaquín Zúñiga
Journal:  J Immunol Res       Date:  2021-04-27       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.